Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
InMed Pharmaceuticals Inc. stock logo
IN
InMed Pharmaceuticals
C$4.19
C$3.35
C$13.86
C$33.73MN/A29,552 shs17,035 shs
MediPharm Labs Corp. stock logo
LABS
MediPharm Labs
C$0.09
+13.3%
C$0.08
C$0.06
C$0.10
C$34.34M0.97219,479 shs338,426 shs
Meta Platforms, Inc. stock logo
META
Meta Platforms
$471.85
+0.8%
$488.01
$235.33
$531.49
$1.19T1.2120.74 million shs10.47 million shs
Zomedica Corp. stock logo
ZOM
Zomedica
$0.14
$0.00
$0.12
$0.25
$136.90M0.995.40 million shs17.05 million shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
InMed Pharmaceuticals Inc. stock logo
IN
InMed Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
MediPharm Labs Corp. stock logo
LABS
MediPharm Labs
+6.25%+6.25%+6.25%+21.43%+6.25%
Meta Platforms, Inc. stock logo
META
Meta Platforms
+0.82%+0.77%-7.82%-0.30%+97.54%
Zomedica Corp. stock logo
ZOM
Zomedica
0.00%0.00%-7.20%-3.27%-35.03%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
InMed Pharmaceuticals Inc. stock logo
IN
InMed Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
MediPharm Labs Corp. stock logo
LABS
MediPharm Labs
N/AN/AN/AN/AN/AN/AN/AN/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
3.8408 of 5 stars
2.43.01.70.02.53.33.1
Zomedica Corp. stock logo
ZOM
Zomedica
0.116 of 5 stars
0.01.00.00.01.81.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
InMed Pharmaceuticals Inc. stock logo
IN
InMed Pharmaceuticals
N/AN/AN/AN/A
MediPharm Labs Corp. stock logo
LABS
MediPharm Labs
N/AN/AN/AN/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
2.89
Moderate Buy$509.808.04% Upside
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/A

Current Analyst Ratings

Latest LABS, IN, META, and ZOM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderperform$360.00
5/1/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$555.00 ➝ $550.00
4/25/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$590.00 ➝ $550.00
4/25/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$550.00 ➝ $535.00
4/25/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$590.00 ➝ $530.00
4/25/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$520.00 ➝ $500.00
4/25/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$550.00 ➝ $520.00
4/25/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$600.00 ➝ $570.00
4/25/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$590.00 ➝ $565.00
4/25/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$540.00 ➝ $500.00
(Data available from 5/15/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
InMed Pharmaceuticals Inc. stock logo
IN
InMed Pharmaceuticals
C$574.68K0.00N/A10.40C$0.76 per share0.00
MediPharm Labs Corp. stock logo
LABS
MediPharm Labs
C$33.06M1.04C$0.07 per share1.30C$0.13 per share0.65
Meta Platforms, Inc. stock logo
META
Meta Platforms
$134.90B8.87$19.54 per share24.15$60.08 per share7.85
Zomedica Corp. stock logo
ZOM
Zomedica
$25.19M5.57N/AN/A$0.24 per share0.60

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
InMed Pharmaceuticals Inc. stock logo
IN
InMed Pharmaceuticals
N/A-C$1.51N/AN/AN/AN/AN/AN/AN/A
MediPharm Labs Corp. stock logo
LABS
MediPharm Labs
-C$13.08M-C$0.04N/AN/A-39.57%-24.00%-12.01%6/28/2024 (Estimated)
Meta Platforms, Inc. stock logo
META
Meta Platforms
$39.10B$17.4127.1020.411.2432.06%32.03%21.21%7/24/2024 (Estimated)
Zomedica Corp. stock logo
ZOM
Zomedica
-$34.53M-$0.04N/AN/A-143.67%-8.62%-8.17%N/A

Latest LABS, IN, META, and ZOM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024Q1 2024
Zomedica Corp. stock logo
ZOM
Zomedica
N/A-$0.01-$0.01-$0.01N/A$6.26 million    
4/24/2024Q1 2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
$4.32$4.71+$0.39$4.71$36.28 billion$36.46 billion    
4/1/2024Q4 2023
Zomedica Corp. stock logo
ZOM
Zomedica
N/A-$0.01-$0.01N/A$7.00 million$7.34 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
InMed Pharmaceuticals Inc. stock logo
IN
InMed Pharmaceuticals
N/AN/AN/AN/AN/A
MediPharm Labs Corp. stock logo
LABS
MediPharm Labs
N/AN/AN/AN/AN/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
$2.000.42%N/A11.49%N/A
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
InMed Pharmaceuticals Inc. stock logo
IN
InMed Pharmaceuticals
8.48
2.13
1.45
MediPharm Labs Corp. stock logo
LABS
MediPharm Labs
4.33
3.37
3.10
Meta Platforms, Inc. stock logo
META
Meta Platforms
0.12
2.68
2.68
Zomedica Corp. stock logo
ZOM
Zomedica
N/A
11.50
10.87

Ownership

Institutional Ownership

CompanyInstitutional Ownership
InMed Pharmaceuticals Inc. stock logo
IN
InMed Pharmaceuticals
N/A
MediPharm Labs Corp. stock logo
LABS
MediPharm Labs
0.73%
Meta Platforms, Inc. stock logo
META
Meta Platforms
79.91%
Zomedica Corp. stock logo
ZOM
Zomedica
8.95%

Insider Ownership

CompanyInsider Ownership
InMed Pharmaceuticals Inc. stock logo
IN
InMed Pharmaceuticals
N/A
MediPharm Labs Corp. stock logo
LABS
MediPharm Labs
2.47%
Meta Platforms, Inc. stock logo
META
Meta Platforms
13.71%
Zomedica Corp. stock logo
ZOM
Zomedica
4.18%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
InMed Pharmaceuticals Inc. stock logo
IN
InMed Pharmaceuticals
128.05 millionN/ANot Optionable
MediPharm Labs Corp. stock logo
LABS
MediPharm Labs
130404.05 millionN/ANot Optionable
Meta Platforms, Inc. stock logo
META
Meta Platforms
67,3172.54 billion2.19 billionOptionable
Zomedica Corp. stock logo
ZOM
Zomedica
144979.95 million938.99 millionNot Optionable

IN, META, ZOM, and LABS Headlines

Recent News About These Companies

Zomedica earnings: here's what Wall Street expects
Q4 2023 Zomedica Corp Earnings Call
Zomedica reports Q4 results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

InMed Pharmaceuticals logo

InMed Pharmaceuticals

TSE:IN
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
MediPharm Labs logo

MediPharm Labs

TSE:LABS
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada and internationally. The company formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. It also provides GMP flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll products. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.
Meta Platforms logo

Meta Platforms

NASDAQ:META
Meta Platforms, Inc. engages in the development of products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and wearables worldwide. It operates in two segments, Family of Apps and Reality Labs. The Family of Apps segment offers Facebook, which enables people to share, discuss, discover, and connect with interests; Instagram, a community for sharing photos, videos, and private messages, as well as feed, stories, reels, video, live, and shops; Messenger, a messaging application for people to connect with friends, family, communities, and businesses across platforms and devices through text, audio, and video calls; and WhatsApp, a messaging application that is used by people and businesses to communicate and transact privately. The Reality Labs segment provides augmented and virtual reality related products comprising consumer hardware, software, and content that help people feel connected, anytime, and anywhere. The company was formerly known as Facebook, Inc. and changed its name to Meta Platforms, Inc. in October 2021. The company was incorporated in 2004 and is headquartered in Menlo Park, California
Zomedica logo

Zomedica

NYSEAMERICAN:ZOM
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.